PharmaShots | Incisive News in 3 Shots

Subscribe Now

psoriatic arthritis

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis...

November 10, 2021

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis...

November 10, 2021

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis

June 8, 2021

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis

June 8, 2021

AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

April 8, 2021

AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

April 8, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us